The effects of 6-hydroxydopamine on vagal cardioaccelerator systems.
D000818:Animals; D001285:Atropine / Q000494:pharmacology; D001949:Bretylium Compounds / Q000494:pharmacology; D002339:Carotid Arteries / Q000502:physiology; D002395:Catecholamines / Q000378:metabolism; D003714:Denervation; D003864:Depression, Chemical; D004285:Dogs; D004558:Electric Stimulation; D006321:Heart / Q000294:innervation; D006339:Heart Rate / Q000187:drug effects*; D006892:Hydroxydopamines / Q000494:pharmacology*; D066298:In Vitro Techniques; D009206:Myocardium / Q000378:metabolism; D009411:Nerve Endings / Q000187:drug effects; D013050:Spectrometry, Fluorescence; D013268:Stimulation, Chemical; D013564:Sympathetic Nervous System / Q000187:drug effects; D013997:Time Factors; D014630:Vagus Nerve / Q000187:drug effects*
D001949:Bretylium Compounds; D002395:Catecholamines; D006892:Hydroxydopamines; D001285:Atropine